Former Neuralink co-founder and now-CEO of Science Corp., Max Hodak, is pushing far beyond the brain-computer interface work that defined his early career. Science Corp. has already acquired and refined a retinal-implant technology — dubbed Prima — which, in clinical trials, enabled about 80 percent of blind patients to read again letter by letter. But the bigger ambition is far more radical: using biohybrid devices and stem-cell derived neurons to literally grow new brain tissue on artificial interfaces, potentially enabling massive expansion of cognitive capacity — and maybe even laying the groundwork for “substrate-independent” consciousness. Hodak says these breakthroughs could start seeing serious human use by 2035, shifting science fiction concepts into real-world possibilities.
Sources: StartUp News, Daily Dev
Key Takeaways
– Science Corp. has already demonstrated near-term, tangible impact: its Prima retinal implant helped most trial participants regain readable vision — a milestone in sensory restoration.
– Beyond implants, the company targets a much more audacious goal: engineering biohybrid neural tissue, effectively growing new brain cells on artificial substrates to reroute or expand cognitive functions.
– If successful, these innovations may challenge existing medical and ethical frameworks — imagining a future where consciousness is decoupled from the biological body and brain-uploading becomes conceivable.
In-Depth
When you think of restoring lost function in humans — vision, mobility, hearing — the typical picture still involves prosthetics or assistive devices: glasses, wheelchairs, cochlear implants. What Max Hodak and his company are chasing goes far beyond that. With Science Corp., Hodak isn’t just tweaking existing hardware to help people; he’s trying to re-engineer what it means to be wired like a human. And make no mistake — the first steps already feel real.
Their current flagship offering, Prima, isn’t a sci-fi concept. It’s a retinal chip, now proven in clinical trials to restore reading ability — letter by letter — to blind patients who’d long given up on such a thing. This isn’t fuzzy light perception or ambiguous shadows; it’s deliberate, functional vision. That alone stands to make a profound difference in the lives of thousands, perhaps millions, of people with degenerative eye conditions.
But Hodak isn’t stopping there. The long game he’s laying out is much, much bigger. Science Corp. is exploring “biohybrid” brain implants — flexible, surface-mounted array devices that carry engineered neurons grown from stem cells. In lab mice, these implants reportedly formed real neural connections: neurons infiltrated into brain tissue, made synapses, and actually influenced behavior (e.g. causing mice to move left or right in response to stimulation). That might sound speculative — even fringe — but to Hodak and his team, it represents a plausible path toward scaling neural interfaces into the millions of channels — far beyond what traditional electrodes could safely support.
What could that lead to? Hodak doesn’t hesitate. He talks about solving the “binding problem” — the fundamental mystery of how subjective consciousness emerges from biological neurons. His long-term vision is startling: humans not just augmented, but re-imagined. Consciousness might be shifted: relocated to engineered neural tissue, or shared across devices, or even hosted in substrates other than organic brains. In other words — uploading, mind-sharing, and cognitive enhancement on a level science fiction writers have only dared suggest.
There are massive ethical, medical, and social questions baked into this. Who gets access to these breakthroughs? Will they reinforce inequality — made available only to the wealthy? How will the regulatory system handle such radical interventions on identity and cognition? How do you ensure long-term safety when you’re implanting living, lab-grown neurons in human brains?
Still, in a world where progress often lags dreams, this isn’t pipe-dreaming. Hodak and Science Corp. are moving with a strategy: start with sensory restoration and build credibility, then quietly expand into more ambitious territory. The regulatory path for restoring vision may be navigable. And if they succeed — even partially — the stakes could outsize any medical advance in history, reshaping not just how we treat disease, but how we define what it is to be human.